A highly potent antibody effective against SARS-CoV-2 variants of concern.

Details

Ressource 1Download: cell report.pdf (4653.47 [Ko])
State: Public
Version: Final published version
License: All rights reserved
Serval ID
serval:BIB_6CC56B59453A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A highly potent antibody effective against SARS-CoV-2 variants of concern.
Journal
Cell reports
Author(s)
Fenwick C. (co-first), Turelli P. (co-first), Perez L. (co-first), Pellaton C., Esteves-Leuenberger L., Farina A., Campos J., Lana E., Fiscalini F., Raclot C., Pojer F., Lau K., Demurtas D., Descatoire M., Joo V.S., Foglierini M., Noto A., Abdelnabi R., Foo C.S., Vangeel L., Neyts J., Du W., Bosch B.J., Veldman G., Leyssen P., Thiel V., LeGrand R., Lévy Y., Trono D., Pantaleo G.
ISSN
2211-1247 (Electronic)
Publication state
Published
Issued date
12/10/2021
Peer-reviewed
Oui
Volume
37
Number
2
Pages
109814
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date. Structural characterization of P5C3 Fab in complex with the spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2-infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals.
Keywords
General Biochemistry, Genetics and Molecular Biology, SARS-CoV-2, neutralizing antibodies, variants of concern
Pubmed
Web of science
Open Access
Yes
Funding(s)
Swiss National Science Foundation
CHUV
Create date
04/10/2021 8:57
Last modification date
21/11/2022 8:24
Usage data